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It has become obvious that several interstitial lung diseases, and even viral lung infections, can progress rapidly, and exhibit similar
features in their lung morphology. The ﬁnal histopathological feature, common in these lung disorders, is diﬀuse alveolar damage
(DAD). The histopathology of DAD is considered to represent end stage phenomenon in acutely behaving interstitial pneumonias,
such as acute interstitial pneumonia (AIP) and acute exacerbations of idiopathic pulmonary ﬁbrosis (IPF). Acute worsening and
DAD may occur also in patients with nonspeciﬁc interstitial pneumonias (NSIPs), and even in severe viral lung infections where
there is DAD histopathology in the lung. A better understanding of the mechanisms underlying the DAD reaction is needed to
clarify the treatment for these serious lung diseases. There is an urgent need for international eﬀorts for studying DAD-associated
lung diseases, since the prognosis of these patients has been and is still dismal.
1.Introduction
Acutely behaving interstitial lung diseases (ILDs) comprise
several diseases with both known and unknown causes.
A common feature in these acute manifestations is the
appearance of diﬀuse alveolar damage (DAD) in the lung,
which is generally associated with very bad prognosis and
high mortality of the patients. An acute ILD may be a rapidly
evolving idiopathic or nonidiopathic disease, it may occur
as the ﬁrst symptom or it may represent a predilection of a
chronic lung disease, or alternatively, it can be encountered
as an acute manifestation of a chronic ILD. The pathogenetic
mechanisms underlying each of these disorders and their
acute exacerbations are largely unknown. From a clinical
point of view, the diagnostics and treatment of these patients
are very demanding, since in addition to the diﬀerential
diagnostics mentioned above, diagnostic procedures have to
exclude infections, drug reactions, and other diseases such
as cardiac diseases and pulmonary embolisms and other
clinical manifestations resembling acute respiratory distress
syndrome (ARDS), such as diﬀuse alveolar hemorrhage
(DAH) and acute ﬁbrinous organizing pneumonia (AFOP).
Moreover, the nomenclature of these diseases has changed
in the past decade and thus it is not uncommon that
many specialists, for example pulmonologists, pathologists,
radiologists and intensive care specialists, may refer to the
same disorder by diﬀerent terms. Patients suﬀering from
aggressive ILDs are very challenging for many specialists,
not least for pulmonologists also due to the appearance of
unpredictable acute disease exacerbations.
2. DAD asa Pathological Phenomenon in
the Lung
First studies on DAD have been published over 40 years
ago, but the phenomenon is still a mystery. In one of the
ﬁrst studies on this issue Cederberg et al. described hyaline
membranes at autopsy of patients who had received oxygen
athighconcentrations[1].Althoughthehistologicalfeatures2 Pulmonary Medicine
of DAD were described even earlier, the name of diﬀuse
alveolar damage, that is, DAD, was presented by Katzenstein
and co-authors in their comprehensive review article, which
included also their own data of over 400 patients with DAD
a n dr o l eo fo x y g e n ,s h o c k ,a n dr e l a t e df a c t o r s[ 2]. They
concluded that DAD is a nonspeciﬁc reaction of the lung
to a multitude of injurious agents, and that endothelial and
alveolar cell injury leads to ﬂuid and cellular exudation,
with hyaline membranes and edema being well-known
features. A few years later Askin & Katzenstein reported that
pneumocystis infection may masquerade DAD [3]. A later
study revealed autopsy ﬁndings of 17 patients with acquired
immunodeﬁciency syndrome (AIDS) of which most had
DAD in their lungs cytomegalovirus and/or pneumocystis
carinii being a most likely etiology [4]. One of the ﬁrst
immunohistochemical studies on this issue in humans was
publishedin1995whenastudybyMatsubaraandco-authors
showed destruction of the alveolar basement membrane in
DAD [5]. Studies on matrix metalloproteinases (MMPs)
and their tissue inhibitors (TIMP) in DAD and idiopathic
pulmonary ﬁbrosis (IPF) demonstrated that both factors
are associated with myoﬁbroblasts and epithelial cells [6].
Subsequent study revealed the presence of α-smooth muscle
actin positive myoﬁbroblasts in the proliferative phase of
DAD [7]. Hyaline membranes of patients with DAD showed
such a heterogeneity, which may suggest that these structures
might be formed by diﬀerent mechanisms in DAD of various
aetiologies[8].Toconclude,thestudiesofthehistopathology
and pathogenesis of DAD in human lung are sparse, and so
far very little has been learnt about its pathogenesis after
the review article of Katzenstein and co-authors which was
published nearly four decades ago.
3.Idiopathic InterstitialPneumoniasThat May
Behave Acutely with DAD Histopathology
Idiopathic interstitial pneumonias (IIP) comprise a disease
group that belongs to the ILDs. The classiﬁcation of IIPs
has changed several times within the past ﬁve decades [9,
10]. In the current classiﬁcation, the histological pattern
and clinico-radiographic-pathologic diagnosis are named
with diﬀerent terms [11]( Table 1). The reason for this
kind of double nomenclature system is that many histologic
patterns are presented not only in idiopathic diseases, but
also are associated with other disorders such as connective
tissue, that is, collagen vascular diseases (CVD) and drug
reactions. Since the clinical behaviour of the idiopathic and
nonidiopathic forms of IIPs may be diﬀerent, it is reasonable
to deﬁne these diseases clinically with other terms. In the
present review, in particular IPF with the histopathology of
usual interstitial pneumonia (UIP), nonspeciﬁc interstitial
pneumonia (NSIP) and acute interstitial pneumonia (AIP)
are described since all of them can behave aggressively
and may be associated with DAD in the lung (Table 2). It
should be stressed, however, that DAD is more frequent
in the patients with IPF than in NSIP. The other types
of interstitial pneumonias generally follow a more benign
course and have not therefore been included in this paper.
In addition there is a recent review on acute exacerbations
of interstitial lung diseases, but that paper included also
sarcoidosis and vasculitides and detailed suggestions for the
treatment of these disorders [12]. Sarcoidosis and vasculitis
are now excluded due to the systemic manifestations of those
disorders.
3.1. IPF. IPF is the most common IIP, accounting for about
25% of the all interstitial pneumonias [11]. In Finland, its
prevalence has been estimated to be 16–18/100000, being
more common in males aged 50–70 years than in females
[13]. It is usually a progressive disease with the average
survival being no more than 2–4 years after diagnosis
[14]. No eﬃcacious medical treatment is currently available,
and the only potential cure may be lung transplantation
(Table 2). Aggregates of ﬁbroblasts and myoﬁbroblasts, that
is, ﬁbroblast foci (FF) are a characteristic of UIP, even
though these cell types may be present also in other types
of pulmonary ﬁbroses (e.g., CVDs and asbestosis) to a
lesser extent [15]. Some of the patients experience acute
exacerbation (AE) with concurrent DAD histopathology that
signiﬁcantly worsens the prognosis. Preventing, predicting
and treating these AEs are key issues in the long-term
followupof thesepatients, butunfortunatelyallarecurrently
unresolved.
3.2. NSIP. NSIP was described in 1995 by Katzenstein and
Fiorelli [16]. It is a disease that may be idiopathic, although
it is the most common type of interstitial pneumonias
associated with many CVDs [17]. Patients with NSIP are
usually younger than their counterparts with IPF, and it
occurs more often in women than in men. Children may also
suﬀer NSIP as an idiopathic disease or as a CVD-associated
disease [18]. NSIP may progress slowly or it can present as a
nonprogressing disease; it may also respond to corticosteroid
treatment and also in that respect it diﬀers from IPF. Most,
that is 74%–82%, of NSIP patients are still alive 5 years
after diagnosis [19, 20]. NSIP has been divided into cellular
and ﬁbrosing patterns, of which the latter may resemble
IPF in its clinical course and prognosis [21]. The histology
of NSIP is usually uniform. In the cellular type of NSIP,
chronic interstitial inﬂammatory cells involves the alveolar
walls, whereas the ﬁbrotic form of NSIP may include more
advanced ﬁbrosis [16, 21]. The prognosis of the ﬁbrotic type
of NSIP is dismal, and the problems encountered including
AE and DAD are very similar as in the above described
disease, IPF.
3.3. AIP. AIP was ﬁrstly described by Hamman and Rich
in 1935 [22]. For many decades the patients in this ﬁrst
paper were assumed to have been suﬀering from UIP/IPF,
in fact, it was 1990 when these patients were shown to
truly suﬀer from AIP [23]. Clinically AIP presents as a
rapid development of respiratory failure in a previously
healthy person [24, 25]. Both clinically and radiologically,
it usually displays the features of ARDS, but in contrast
to ARDS, no speciﬁc cause as an aetiology can be found,
therefore it could be considered as “idiopathic ARDS”
[26, 27]( Figure 1(a)–1(d)). The histological pattern of AIP
is typically DAD with hyaline membranes, edema, andPulmonary Medicine 3
Table 1: Classiﬁcations of interstitial pneumonias.
Liebow 1969 Katzenstein & Myers 1998 ATS & ERS Statement 2002 ATS & ERS Statement 2002
Histological pattern Clinico-radiographic-pathological diagnosis
UIP UIP UIP IPF
DIP DIP DIP DIP
RB-ILD RB-ILD RB-ILD
LIP LIP LIP
GIP
BIP OP COP
AIP DAD AIP
NSIP NSIP NSIP
UIP: usual interstitial pneumonia
IPF: idiopathic pulmonary ﬁbrosis
DIP: desquamative interstitial pneumonia
RB-ILD: respiratory bronchiolitis interstitial pneumonia
LIP: lymphocytic interstitial pneumonia
GIP: giant cell interstitial pneumonia
BIP: bronchiolitis obliterans interstitial pneumonia
OP: organizing pneumonia
COP: cryptogenic organizing pneumonia
AIP: acute interstitial pneumonia
DAD: diﬀuse alveolar damage
NSIP: nonspeciﬁc interstitial pneumonia.
Table 2: Idiopathic interstitial pneumonias that may behave acutely.
IPF AIP NSIP
Age/sex 50–70 years, more common in males All ages, as common in females than in
males
40–60 years, also in children.
More common in females
Survival Most of the patients had died after 2–4
years after of diagnosis
In-hospital mortality 12%–50%, 70%
mortality in 6 months 5 year survival 74%–82 %
Course of disease
Usually slowly progressive over within
years, sometimes rapidly, acute
exacerbations may occur
Acute lower respiratory tract illness
within 60 days
Stable or slowly progressing, acute
exacerbations may occur
Treatment No currently known eﬃcient
treatment. Corticosteroids Immunosuppressants Corticosteroids Immunosuppressants
Radiology
Honeycombing, reticulation,
bronchiectasis and bronchiolectasis.
Ground glass opacities and
consolidations in AE.
Diﬀuse ground glass opacities and
inﬁltrates
Ground glass opacities.
No or scant honeycombing
Histopathology
Heterogenous appearance with areas
of normal parenchyma, ﬁbrosis and
honeycomb cysts, which is termed as
UIP. AE of UIP show also DAD in
addition to UIP.
DAD with hyaline membranes,
¨ oedema and interstitial acute
inﬂammation in acute phase. In
organizing phase alveolar septal
thickening with organizing ﬁbrosis,
type II pneumocyte hyperplasia, and
patchy or diﬀuse airspace
organization.
In cellular type of NSIP, chronic
interstitial inﬂammatory cells involves
alveolar walls, ﬁbrotic form may
include more advanced ﬁbrosis.
The histology is usually uniform. In
AE of NSIP also DAD is present.
interstitial acute inﬂammation [28]. In the organizing phase
of DAD (approximately 5–10 days after injury), alveolar
septal thickening with loose organizing ﬁbrosis, type II
pneumocyte hyperplasia, and patchy or diﬀuse airspace
organization can be found (Figure 1(c)). The prognosis of
AIP is dismal and the mortality high. It has been suggested
that by adopting an aggressive diagnostic approach, that is,
mechanical ventilation with a lung-protective strategy, and
the early institution of immunosuppressive therapy it may
be possible to improve the clinical outcome of AIP [29–31].
Controlled prospective studies on the treatment of AIP are
notavailable,notsurprisingsinceAIPissouncommonandit
is generally a very acute lung manifestation displaying some
overlapping features with ARDS.4 Pulmonary Medicine
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Figure 1: Radiological and histological ﬁndings of an AIP patient who was actively treated by mechanical ventilation and high doses of
corticosteroids and immunosuppressive drugs. (a) Chest X-ray showing alveolar inﬁltrates at the time when the patient was mechanically
ventilated. (b) HRCT ﬁndings of the upper lung lobes showing ground glass opacity and inﬁltrates. HRCT was taken on the following day
after the chest X-ray shown in panel (a) Both Chest-X-ray and HRCT have been taken 2-3 days before taking the lung biopsy by VATS. (c)
Lung biopsy ﬁndings of the same patient showing interstitial ﬁbrosis and ﬁbroblast proliferation representing late stages of organizing phase
of DAD after treatment of several weeks. The patient recovered well with minimal radiological (d) and functional abnormalities within the
lungs documented 4 years after the episode.
4. Acute Exacerbation of IPF
Although IPF is usually a relentlessly, progressive disease
lasting for months, even years, it may also start with an
insidious onset and display AEs, in which the typical
features are worsening dyspnea, cough, low-grade fever,
worsening gas-exchange parameters, and the appearance of
new opacities in radiology [32, 33]. This condition needs to
be diﬀerentiated from AIP, in which the patients have not
had a previous lung disease. There are no universal accepted
diagnostic criteria for AE of IPF, although the criteria
have been proposed by Kondoh, Akira, and Kim and most
recently the IPF Clinical Research Network Investigators
(Table 3)[ 32–35], that is, worsening of dyspnoea within
one month and deterioration of gas-exchange parameters,
combined with the exclusion of heart diseases, pulmonary
embolisms, and infections (Table 3). A recent study showed
that one-year and three-year incidence of AE of IPF was
14.2% and 20.7%, respectively [36].
The etiology of AE of IPF is unknown, although some
published case reports have proposed that bronchoalveolar
lavage (BAL) or lung biopsy procedures, or certain drugs
or treatments might trigger AE in some IPF patients [37,
38]. A recent study claimed that in patients with IPF, the
presenceofongoingAEatthetimeofthelungbiopsysurgery
represented a marked risk factor for complications and
mortality [39]. Circulating ﬁbrocytes have been shown to be
elevated in patients with stable IPF, with a further increasePulmonary Medicine 5
Table 3: Proposed criteria of AE of IPF by Collard and the IPF Clinical Research Network Invertigators [34].
Previous or concurrent diagnosis of IPF
Unexplained worsening or development of dyspnea within 30 days
HRCT with new bilateral ground-glass abnormality and/or consolidation superimposed on a background reticular or honeycomb
pattern consistent with UIP pattern
No evidence of pulmonary infection by endotracheal aspirate or bronchoalveolar lavage
Exclusion of alternative causes, including the following: left heart failure, pulmonary embolism, identiﬁable cause of acute lung
injury
occurring during AE of IPF, whereas the patients with ARDS
were not diﬀerent from healthy control subjects or stable
patients with IPF [40]. Another recent study observed that
a total of 579 genes were diﬀerentially expressed between
stable IPF and AE of IPF, however a functional analysis of
these genes did not reveal any evidence of an infectious or
inﬂammatory aetiology [41]. Overall, the results obtained
from the gene expression proﬁles identiﬁed epithelial injury
and proliferation as the key molecular genetic events in AE
and proposed that plasma defensins could be considered as
new biomarkers for the acute disease exacerbation. A quite
recent study by Collard and co-authors interestingly showed
that plasma from patients with AE of IPF showed signiﬁcant
elevations in markers of type II alveolar epithelial cell injury
and/or proliferation, endothelial cell injury, and coagulation,
and moreover, that this proﬁle diﬀered from the biomarker
proﬁle of the patients with acute lung injury [42].
AE of IPF presents with radiological changes in addition
to the typical IPF-alterations, which especially in lower
lungs, include peripheral predominant, basal predominant
reticular abnormalities, with honeycombing and traction
bronchiectasis and bronchiolectasis [43]. Akira and co-
authors studied 58 IPF-patients with AE [44]. Two radiol-
ogists evaluated the features with high-resolution computed
tomography (HRCT). In this evaluation, the overall extents
of the parenchymal changes, consolidations, reticulation,
and honeycombing were noted. The HRCT changes were
classiﬁed into three types, namely, peripheral, multifocal,
and diﬀuse patterns. That particular study showed that
during the AE process the radiological and HRCT changes
may vary, and that a peripheral pattern is a common
phenomenon. The conclusion from the radiological studies
is that it appears that the shortest survival of AE of IPF is
associated with diﬀuse abnormality in HRCT [44].
Based on a systematic review of 8 published studies, each
of which had rather small numbers of IPF patients with AE,
most of the cases were men between 65–70 years, whose
lung function tests were relatively good, suggesting that the
clinical course of the disease had been at an early phase
[33, 35, 38, 45–50]. Nearly all patients displayed neutrophilia
in the BAL ﬂuid, ground glass opacities, and consolidation
in HRCT. Importantly all biopsied cases presented DAD
superimposed on UIP lung histopathology. The prognosis
of AE was poor in both the mechanically invasively and the
noninvasively treated groups, since most of the patients had
died within one month after the AE despite active medical
treatment [45]. At present there is no consensus about
the treatment of AE of IPF, although most patients receive
therapy with corticosteroids and other immunosuppressive
drugs. One study evaluating the use of pirfenidone in
patients with IPF had to be terminated prematurely because
in the placebo-control group the patients suﬀered more AEs
than occurred in the pirfenidone group, indicating that the
d ru gm i gh th a v es o m ee ﬃcacy in the prevention of AE of IPF
[51]. These suggestions need to be conﬁrmed in the future
before any therapeutic conclusions can be drawn. Eﬀorts
in recognizing and predicting the exacerbation as early as
possible are of major signiﬁcance for the overall treatment of
the patient, including the possibility of lung transplantation.
5. Acute Exacerbations in Other
InterstitialLungDiseases
In addition to IPF, AEs have been shown to occur in other
types of ILDs. Based on one study of 74 patients with
idiopathicNSIPand93patientswhohadbothCVDandILD,
AE occurred in six patients with idiopathic NSIP and in four
patients with CVD-ILD, that is, in rheumatoid arthritis and
scleroderma[39].Inthatstudy,AEwasdiagnosedbytheAki-
ras criteria, and in two cases it took place immediately after
surgical lung biopsy. Again the lung biopsy ﬁndings showed
DAD in addition to NSIP. Another recent study examined
patients with surgical lung biopsy proven ﬁbrotic hyper-
sensitivity pneumonitis that is, allergic alveolitis, who had
experienced an acute decline in their respiratory status and
who met criteria similar to those proposed for the diagnosis
of an AE of IPF [52]. These patients experienced a clinical
course similar to that of AE of IPF. All cases resulted either
in death of the patient or lung transplantation. Lung biopsy
at the time of AE or autopsy revealed organizing DAD super-
imposedonﬁbroticlungdisease[52–54].Inarecentstudyof
83biopsiedpatientswithCVDandILD,ﬁvepatientssuﬀered
fromrheumatoidarthritisandonepatientfromscleroderma,
which associated either with UIP, NSIP, or unclassiﬁable ILD
change and AE. Five of these patients died despite active
treatments that included invasive mechanical ventilation and
immunosuppressive medication [55]. The prognosis of the
patients with CVD is generally signiﬁcantly better compared
to IPF. It can, however, be concluded that AEs in these other
interstitiallungdiseasescanexhibitverysimilarclinical,radi-
ological, and histological ﬁndings. It needs to be emphasized
also that the lung manifestations of systemic diseases are
complex and therefore need to be evaluated very carefully.6 Pulmonary Medicine
6. IntensiveCareTreatment andAE of ILDs
The development of DAD is still poorly understood, and
most treatments are empiric. Several studies have indicated
that IPF patients with acute lung failure do not beneﬁt from
intensive care treatment and invasive mechanical ventilation
[56–61]. It has been also proposed that invasive mechanical
ventilation should be used only in those patients who
are scheduled to undergo a lung transplantation operation
within a few days. When an ILD patient experiences an
acute lung failure, there are many possible causes to be
considered in the diagnostics for example, deterioration of
chronic lung diseases, infections, AE of the disease, or drug
reactions. Recent guidelines published by the British Tho-
racicSocietyrecommendpalliativetreatmentforthepatients
with AE of IPF, whereas those ILDs that are reversible,
need to be diagnosed and treated actively [62]. Thus the
reversibleILDwithacuterespiratoryfailureshouldbetreated
by intensive care treatment with mechanical ventilation,
and thus BAL, transbronchial biopsy and surgical lung
biopsy should be considered as the diagnostic procedures.
Taken together, current invasive/intensive treatment has no
deﬁnitive role in AE of IPF, while intensive treatment and
methods of extensive diagnostics should be considered in
the acute exacerbations of the other ILDs. However, in
reality it is often very diﬃcult to exclude infections of
the IPF patients experiencing an acute deterioration, and
therefore careful consideration is needed especially with
those patients who may beneﬁt from a lung transplantation
operation.
7.LungBiopsy inMechanically
Ventilated Patients
The lung biopsy procedure of mechanically ventilated
patients has been previously assumed to carry a high risk
for patients and thus it cannot be recommended [63–65].
However, recent studies have indicated, that lung biopsy
operation is relatively safe, and it has been shown to be
a rather secure procedure, even in mechanically ventilated
patients [66–68]. Lim and co-authors studied 36 mechani-
callyventilatedpatientswithundiagnoseddiﬀusepulmonary
inﬁltrates who had undergone an open lung biopsy proce-
dure for diagnostic purposes. The most common ﬁndings
of the lung biopsies were IIPs, of which AIP was the
most common type, occurring in 8 patients. Three of
these patients had AE of IPF. In addition to the interstitial
pneumonias, single cases of infections and drug reactions
were also observed. The most common complication was a
prolonged air leakage occurring in ﬁfteen patients out of 36
(42%);none of thecomplications werefatal.Thelung biopsy
ﬁndingschanged thetreatmentsin 64% of thepatients. Ifthe
open lung biopsy has been conducted within one week after
the initiation of mechanical ventilation, there was improved
prognosis of survival of the patients [69]. To conclude, lung
biopsy can be recommended even in ventilated patients, but
only after careful consideration and if accurate diagnosis is
likely to contribute to the treatment.
8. Associationof DADwith ARDS andOther
A c u t eR eac tio n so ft h eL un g
In 1967, Ashbaugh and co-authors described 12 patients
with acute respiratory distress [70]. A new deﬁnition of lung
injury was recommended in 1994 in which these patients
were separated into two groups, namely, those patients
with less severe hypoxemia being classiﬁed as having acute
lung injury (ALI), and those with more severe hypoxemia
as suﬀering from ARDS [71, 72]. The most common
morphologic pattern of ARDS is DAD, the features of which
correlate better with the phases of alveolar damage than
with its speciﬁc cause. Another histological pattern, which
can be clinically and radiologically expressed as ARDS, is
AFOP. This pattern does not meet the strict histological
criteria for either organizing pneumonia (OP) or DAD
and the prognosis of AFOP is better than DAD. DAD has
been divided into exudative, proliferative, and ﬁbrotic, or
organizing phases [73, 74]. The pathologic alterations seen
in ARDS, however, have been shown to be heterogeneous,
since in a recent study only half of the patients with ARDS
displayed typical DAD in postmortem examination [75].
On the other hand, only less than half of patients with
postmortem autopsy ﬁndings of DAD that were treated in
intensive care unit had been diagnosed clinically as ARDS
[76]. Signiﬁcant diﬀerences between ARDS and AIP are
supported by the large diﬀerences of DAD in the lungs of
ARDS patients, and the known etiological trigger in ARDS
but not in AIP, which are factors that may account for the
variable patient recovery.
A retrospective study on 58 patients with DAD lung
histopathology revealed that 60% of them were immuno-
compromised and 90% of them fulﬁlled the ARDS cri-
teria at the time of the lung biopsy [77]. The causes of
DAD in that particular study were infections (22%), AIP
(21%), non-infectious complication of an organ or stem
cell transplantation (17%), CVD (16%), AE of IPF (12%),
drug reactions (10%) and radiation therapy (2%). The
overall mortality for the lung diseases was 53%, with the
exception of AE of IPF, in which the mortality was higher,
being 86%. The histology of DAD is not able to reveal the
cause of alveolar damage, although a recent study depicted
two forms of DAD in patients with ARDS showing that
interstitial myoﬁbroblast proliferation was more common
in patients with chemotherapy or drug toxicity than with
severe infections [78]. From the clinical point of view, it is
importanttounderstandthatthehistologicalpatternofDAD
is a non-speciﬁc lung reaction, and it does not provide any
information to the clinician about the reason for the disease,
that is, sepsis, trauma, aspiration, infection, drugs or it can
be associated with an idiopathic disease such as AIP.
9. ViralInfections, DADand IPF
DAD is a common lung reaction in patients suﬀering
inﬂuenza infection. A landmark paper by Goodpasture and
co-authors described the autopsy ﬁndings of two patients
who had suﬀered from inﬂuenza in 1918. In both of
the cases, the lungs showed features of DAD includingPulmonary Medicine 7
“hyaline materials upon the walls of dilated alveolar ducts
and in alveoli” which is the typical histological pattern of
DAD. In that particular paper, it was stated that “Both
presented lesions in the lung which are to be regarded as
peculiar to the pulmonary inﬂammation of inﬂuenza, yet no
micro-organisms were demonstrated by the usual methods
in the lungs of either” [79]. In avian inﬂuenza A H5N1 virus
infection and severe acute respiratory syndrome (SARS),
DAD is a common autopsy ﬁnding in the lungs [80–82].
A very recent study described the autopsy ﬁndings of 21
patients with H1N1-inﬂuenza A infection. The age of the
patients varied from 1 to 68 years, with 72% being between
30–59 years. Twenty patients had DAD in their lungs, and
in addition to DAD, the lungs of 6 patients exhibited also
necrotizing bronchiolitis and a furtherﬁve patients displayed
extensive hemorrhage [83]. Overall, the most extensive
manifestations of H1N1-inﬂuenza will be observed in the
lungs and there is a risk for the development of DAD.
Several studies over decade ago have also suggested the
role of viral infections in the pathogenesis of IPF; the viruses
include hepatitis C [84], Ebstein Barr [85], cytomegalo, and
other herpes viral infections [86]. Interestingly recent study
by Vannella and co-workers hypothesized that gammaherpes
viruses can serve as initiating cofactors in the pathogenesis of
pulmonary ﬁbrosis and even its AEs [87]. In line with these
new ﬁndings our recent study identiﬁed that ELMOD2, a
candidate gene for IPF, regulates antiviral responses [88]. It
is highly likely that the role of viral infections in the etiology
and pathogenesis of IPF and other interstitial lung diseases
and their AEs may be more important than previously
assumed.
10. Conclusions
Several idiopathic and nonidiopathic interstitial lung dis-
eases display similar morphological features, namely DAD,
eitherinthestablephaseorespeciallyduringanexacerbation
of the disease (Table 4). In IPF, NSIP, CVD-ILD, and allergic
alveolitis,acuteexacerbationsmayoccur,inwhichthetypical
histologicalfeaturesofthediseasearesuperimposedonDAD
pathology. In addition to the IIPs including AIP, a clinical
ARDS is also a DAD disease in its pathological features.
Moreover, the most serious manifestations of inﬂuenza viral
infections are DAD reactions within the lungs, and recent
studies have suggested that viruses may play role in IPF
and its exacerbations. Thus, it seems that in many ways, the
DAD reaction in the lungs may be traced to many causes,
and therefore it might be assumed to represent a serious
nonspeciﬁc reaction in response to variety of triggers. Many
factors in the pathogenesis of DAD remain still unresolved. If
one could understand the mechanisms underlying the DAD
reaction, it might be possible to use this novel information to
develop improved treatment for many lung diseases, which
today are untreatable. One of the major ﬁndings in these
reactions is the injury to alveolar epithelium, and therefore
therapeutic strategies aimed at protecting the epithelium
may represent novel strategies that should be carefully
evaluated in the future.
Table 4: Associations of DAD with interstitial lung diseases and
severe lung reactions (reference number in parentheses).
AIP [28]
AE of IPF [33, 35, 44]
AE of NSIP [39]
AE of CVD associated UIP and NSIP [39]
AE of allergic alveolitis [52]
ARDS [75, 76]
- Infections
- Organ or stem cell transplantation
- Drug reaction
- Radiation therapy
Viral lung infections [79]
-S A R S [ 80, 81]
- H1N1-inﬂuenza A [83]
AE: acute exacerbation
UIP: usual interstitial pneumonia
IPF: idiopathic pulmonary ﬁbrosis
NSIP: nonspeciﬁc interstitial pneumonia
CVD: collagen vascular disease.
11.FuturePerspectives
It is evident that interstitial lung diseases represent a very
heterogenous group of lung diseases, including lung diseases
with known reasons such as allergic alveolitis, connective
tissue diseases associated with lung diseases and infectious
lung disorders and in all of these the acute reaction within
the lung may be similar, namely, DAD. This reaction can be
postulated as representing one of the fundamental injurious
responses of the lung. However, the pathogenetic mecha-
nisms underlying DAD are still mostly unknown, especially
in humans. Most experimental studies have been conducted
with animals exposed to toxins, lipopolysaccharide, and so
forth, and these reactions cannot be directly extrapolated to
human lung since lung reactions occurring in mice and rats
do not resemble exactly those encountered in human lung.
Another limitation for studying DAD in human lung is
therarityofthosediseases.Itisverydiﬃcult,virtuallyimpos-
sible, to gather large numbers of patients/samples of DAD-
associated lung diseases during their acute exacerbations
withoutinternationalcollaborationinvolvingseveralspecial-
ities. It can be argued that the study of DAD-associated lung
diseases is even more diﬃcult than that of IIPs or other types
of relatively rare lung diseases, because DAD is conﬁned
to unpredictable periods of various diseases. A systematic
collection of human lung tissue and cell material would sig-
niﬁcantlyimprovetheclinical-radiological-histopathological
interpretation especially if combined with experimental in
vitro studies in cells established from human lung.
Methods to study disease mechanisms have dramatically
developed during the last decade, while some older state-
ments and conclusions may require new interpretation and
re-evaluation. For example recent evidence has suggested
thatvirusesmayplayanimportantrolenotonlyintheaetiol-
ogy and pathogenesis of ILDs but also in their exacerbations,
and that viruses can directly cause DAD reaction in the lung.8 Pulmonary Medicine
There is need for international eﬀorts and collaborations
to study DAD-associated lung diseases and to discover tar-
geted therapies, since the diseases are uncommon, prognosis
of these patients has been dismal for years and is still very
poor [29], and the patients are being evaluated and treated at
many specialities.
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